



RECEIVED

SEP 04 2002

TECH CENTER 1600/2900

#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1645 .
Claus OXVIG)	Examiner:
Serial No.: 09/983,025)	Confirmation No. 7756
Filed: October 22, 2001)	Washington, D.C.
For: PREGNANCY-ASSOCIATED)	September 3, 2002
PLASMA...)	Docket No.: OXVIG=1A
)	

SECOND INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
Washington, D.C. 20231

S i r :

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed:

☐ A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application. See 37 CFR 1.97(b).

☒ B. before the mailing date of a first office action on the merits. See 37 CFR 1.97(b).

☐ C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below). See 37 CFR 1.97(c).

In re Appl. No. 09/983,025
Confirmation No. 7756

[] i. Counsel certifies that, upon information and belief, each item of information listed herein was either (a) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

[] ii. A check for the fee set forth in 1.17(p), presently believed to be \$180, is enclosed (check no. _____).

[] D. after (A), (B) and (C) above, but before payment of the issue fee. Applicant petitions under 37 C.F.R. 1.97(d) for consideration of this IDS. A check for the fee set forth in 1.17(i)(1), presently believed to be \$130 is enclosed (check no. _____). Counsel certifies that, upon information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

[] E. As a submission in accordance with the transitional procedure for limited examination after final rejection pursuant to 37 CFR §1.129(a). Pursuant to MPEP §706.07(g), page 700-46, col. 2 (February 2000), this IDS is treated as if filed with a period set forth in 37 CFR §1.97(b) and considered without the petition and petition fee required by 1.97(d).

2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other

In re Appl. No. 09/983,025
Confirmation No. 7756

information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document is attached, except as explained below.

☐ A. Documents _____ are deemed substantially cumulative to documents _____, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.

☐ B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

[insert serial number/filing date]

Applicants identify these documents by attaching hereto copies of the form PTO-892s and PTO-1449s from the files of the prior applications or a fresh PTO-1449 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application. If copies of any of these documents cannot be found in the files of the prior applications, the Examiner is requested to so notify counsel before taking action in this case, so replacement copies can be submitted. While an IDS filed under §1.97 must contain a "list of all patents, publications or other information submitted for consideration by the Office", see §1.98(a) (1), the only requirement for the list is that it provide the information set forth in §1.98(b). There is no requirement that a form PTO-1449 be used (MPEP §609 merely says that use of this form is "encouraged") and no prohibition on submitting a copy of a form PTO-1449 or form PTO-892 from a prior case. A previously accepted PTO-1449, or an examiner-prepared PTO-892, necessarily complies with §1.98(b).

☐ 3. Document _ is not in the English language. In accordance with 1.98(c), Applicants state:

☐ a publicly available abstract is attached to each of

In re Appl. No. 09/983,025
Confirmation No. 7756

documents _____, and the source of each abstract is indicated thereon.

- [] documents _____ are patents or published patent applications for which counterpart English language patents or patent applications exist, and are enclosed, as follows:

<u>Foreign Lang. Doc.#</u>	<u>English Lang. Doc.#</u>
[insert]	[insert]

- [] applicants have prepared an English translation of at least the pertinent portions of documents _____, and copies are attached.

- [] A concise explanation of the relevance of documents _____ is found in the attached search report from the _____ Patent Office (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

- [] A concise explanation of the relevance of documents _____ is set forth as follows:

[Insert concise explanation of relevance]

4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. Other information being provided for the examiner's consideration follows:

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.


In re Appl. No. 09/983,025
Confirmation No. 7756

7. The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By:


Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms
G:\BN\H\hoib\Oxvig1A\pto secondids.wpd

Patent application No. 09/983,025 in United States
 "Pregnancy-associated plasma protein-A2 (PAPP-A2)"
 Docket No.: OXVIG=1A

NO.	AUTHOR	TITLE	JOURNAL NAME, VOLUME NUMBER, PAGE NUMBER PUBLICATION DATE
AA	Lawrence J B et al	"The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A"	Proc.Natl. Acad. Sci, USA, vol. 96, pp. 3149-3153, March 1999 (1999-03)
AB	Kristensen T et al.	"Amino acid sequence of human pregnancy-associated plasma protein-A derived from cloned cDNA"	Biochemistry, 33, 1592-1598, February 1994
AC	Overgaard M T et al	"Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor"	The Journal of Biological Chemistry, vol. 275, No. 40, 6, pp. 31128-31133, October 2000
AD	Oxvig C et al.	"Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma"	The Journal of Biological Chemistry, vol. 270, No. 23, pp. 13645-13651, Issue of June 9, 1995
AE	Overgaard M T et al	"Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: Expression in human reproductive and nonreproductive tissues"	Biology of Reproduction, 61, 1083-1089, October 1999
AF	Bonno M et al	"Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta"	Abstract, Laboratory Investigation, vol. 71, no. 4, pages 560-566, October 1994
AG	Drmanac R T et al.	"Novel nucleic acids and polypeptides"	WO01/75067 October 11, 2001

Patent application No. 09/983,025 in United States "Pregnancy-associated plasma protein-A2 (PAPP-A2)" Docket No.: OXVIG=1A			
AH	Erickson G F et al	"The physiology of folliculogenesis: the role of novel growth factors"	Fertility and Sterility, vol. 76, no. 5, pages 943-949, November 2001
AI	Overgaard M T et al.	"Insulin-like growth factor binding protein-4 protease"	WO00/54806 September 21, 2000
AJ	Wald N J et al	"First trimester serum screening for Down's Syndrome"	Prenatal Diagnosis, vol. 15, pages 1227-1240, December 1995

G:\BNI\Htoib\Oxvig\A\pro refslist 2ndids.wpd